RecruitingNot ApplicableNCT06448637

DRUG RELEASING BALL vs. PHARMACOACTIVE STENT IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY) IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY)

DRUG RELEASING BALL vs. PHARMACOACTIVE STENT IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY)


Sponsor

Fundación EPIC

Enrollment

94 participants

Start Date

Oct 23, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Randomized, controlled, open and multicenter study that analyzes the vasomotor function 8 months after use of the drug-eluting balloon (DCB) vs. drug-eluting stent (DES) in vessels ≥ 3.5 mm


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Patients who meet all of the following conditions are included.
  • Patients aged ≥ 18 years and;
  • Patients with chronic coronary syndrome, acute coronary syndrome without ST segment elevation or acute coronary syndrome with elevation ST segment in non-culprit lesions 48 hours after the event and;
  • Patients with de novo lesions in vessels ≥ 3.5 mm without calcification significant no visible thrombus and;
  • Patients who have been informed of the characteristics of the study and have provided their written informed consent.

Exclusion Criteria14

  • Patients who meet at least one of the following conditions are excluded:
  • Patients with any contraindication for the administration of acetylcholine (ACh) or nitroglycerin (NTG).
  • Patients with a history of coronary vasospasm or spontaneous dissection of the coronary artery.
  • Patients with significant medical, surgical or psychiatric condition that would affect the safety of the subject or influence the outcome of the study according to the doctor's opinion.
  • Patients who received a combination of DES and DCB in the same vessel
  • Patients with glomerular filtration rate \<30 ml/min/ 1.73 m2
  • Patients with body mass index \>35 (may affect the evaluation qualitative diameter of the coronary artery).
  • Patients with symptomatic congestive heart failure.
  • Patients with significant autoimmune inflammatory conditions and patients taking immunomodulatory medications (including methotrexate, cyclosporine, steroids).
  • Patients with heart transplant.
  • Patients with anemia (Hb \<12 g/dL in men and \<10 g/dL in women).
  • Patients, women of childbearing age with a positive pregnancy test.
  • Pregnant female patients.
  • Patients included in other clinical trials with active follow-up.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEDrug Coated Balloon (DCB)

Drug Coated Balloon (DCB) in patients with indication of Percutaneous Coronary Intervention (PCI)

DEVICEDrug Eluting Stent (DES)

Drug Eluting Stent (DES) in patients with indication of Percutaneous Coronary Intervention (PCI)


Locations(7)

Hospital Universitari Vall d'Hebron

Barcelona, Spain

Hospital Universitario de Cabueñes

Gijón, Spain

Hospital Universitario Juan Ramón Jiménez

Huelva, Spain

Hospital Universitario de Leon

León, Spain

Hospital Universitario Lucus Augusti

Lugo, Spain

Hospital Universitario Central de Asturias

Oviedo, Spain

Hospital Provincial de Pontevedra

Pontevedra, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06448637


Related Trials